200
Participants
Start Date
December 1, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
XNW28012
Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.
RECRUITING
Second Affiliated Hospital of Anhui Medical University, Hefei
RECRUITING
The First Affiliated Hospital of University of Science and Technology of China, Hefei
RECRUITING
Beijing Friendship Hospital, Capital Medical University, Beijing
RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
Fujian Provincial Cancer Hospital, Fuzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
RECRUITING
Affiliated Hospital of Guizhou Medical University, Guiyang
RECRUITING
Affiliated Hospital of Hebei University, Baoding
RECRUITING
Affiliated Cancer Hospital of Harbin Medical University, Harbin
RECRUITING
First Affiliated Hospital of Henan University of Science and Technology, Luoyang
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
The Second Xiangya Hospital Of Central South University, Changsha
RECRUITING
First Affiliated Hospital of Gannan Medical College, Ganzhou
RECRUITING
First Affiliated Hospital of Kunming Medical University, Yunnan
RECRUITING
Affiliated Hospital of Binzhou Medical College, Binzhou
RECRUITING
Jinan Central Hospital, Jinan
RECRUITING
Linyi Cancer Hospital, Linyi
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Sichuan Provincial People's Hospital, Chengdu
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Yunnan Cancer Hospital, Kunming
RECRUITING
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Lead Sponsor
Evopoint Biosciences Inc.
INDUSTRY